Literature DB >> 26722050

Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia.

Svetlana Kurilovich1, Anna Belkovets2, Oleg Reshetnikov2, Tatyana Openko2, Sofja Malyutina2, Ylija Ragino2, Lilija Scherbakova2, Marcis Leja3, Lea Paloheimo4, Kari Syrjänen5, Mikhail Voevoda2.   

Abstract

BACKGROUND/AIM: Atrophic gastritis (AG) is the most important risk condition for gastric cancer (GC). A panel of stomach-specific serum biomarkers: pepsinogen (PG) I, pepsinogen (PG) II, gastrin-17 (G-17), and IgG antibodies to H. pylori (HP-Ab) detects the extent and grade of AG. The aim of the present study was to assess the predictive value of this 4-biomarker panel (GastroPanel, Biohit Oyj, Helsinki, Finland) in a case-control setting nested within a cohort of Caucasian population in Western Siberia. PATIENTS AND METHODS: Both the cases and controls for the study derived from a population-based cohort of 45-69-year-old subjects (n=9,360) in the HAPIEE (Health, Alcohol and Psychosocial Factors In Eastern Europe) study, enrolled in Novosibirsk, Siberia during 2003-2005. Cases represent all GCs reported to the Cancer Registry until 2012, being matched (1:2) with healthy controls (COs). Altogether 156 (52 GCs and 104 COs) serum samples collected at study entry were available for GastroPanel analysis. Conditional logistic regression models (uni- and multivariate) were used to analyze this matched case-control setting.
RESULTS: The biomarker levels below cut-off at baseline predicted the development of GC as follows: PGI (OR=2.9; 95%CI=1.3-6.4), PGII (OR=9.0; 95%CI=1.8-44.3), PGI/PGII (OR=3.3; 95%CI=1.5-7.3); G-17 (OR=1.8; 95%CI=0.7-4.8), and HP-Ab (OR=0.4; 95%CI=0.1-1.3). In the multivariate model adjusted for sex, age, and all GastroPanel markers, PGI/PGII ratio was the most powerful independent predictor of GC (OR=2.9; 95% CI=1.01-8.0).
CONCLUSION: For the first time in a Caucasian population, we demonstrated that PGI, PGII and PGI/PGII ratio are reliable longitudinal predictors of incidence of GC. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Caucasian race; Gastric cancer; GastroPanel; H. pylori antibody; gastrin-17; longitudinal study; pepsinogen I and II; risk prediction; serum biomarkers

Mesh:

Substances:

Year:  2016        PMID: 26722050

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

Review 1.  Potential Non-invasive Biomarkers of Helicobacter pylori-Associated Gastric Cancer.

Authors:  Fatima Boubrik; Ahmed Belmouden; Nadia El Kadmiri
Journal:  J Gastrointest Cancer       Date:  2021-11-12

2.  Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males.

Authors:  M Song; M C Camargo; S J Weinstein; G Murphy; N D Freedman; J Koshiol; R Z Stolzenberg-Solomon; C C Abnet; S Männistö; D Albanes; C S Rabkin
Journal:  Aliment Pharmacol Ther       Date:  2017-12-15       Impact factor: 8.171

3.  Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study.

Authors:  Marcis Leja; Jin Young Park; Raul Murillo; Inta Liepniece-Karele; Sergejs Isajevs; Ilze Kikuste; Dace Rudzite; Petra Krike; Sergei Parshutin; Inese Polaka; Arnis Kirsners; Daiga Santare; Valdis Folkmanis; Ilva Daugule; Martyn Plummer; Rolando Herrero
Journal:  BMJ Open       Date:  2017-08-11       Impact factor: 2.692

Review 4.  Host pathogen interactions in Helicobacter pylori related gastric cancer.

Authors:  Magdalena Chmiela; Zuzanna Karwowska; Weronika Gonciarz; Bujana Allushi; Paweł Stączek
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

5.  HIV related hypochlorhydria does not appear to respond to anti-retroviral therapy in Zambian adults: a case control study.

Authors:  Violet Kayamba; Aaron Shibemba; Kanekwa Zyambo; Douglas Corbett Heimburger; Douglas Morgan; Paul Kelly
Journal:  Pan Afr Med J       Date:  2018-10-22

6.  Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study.

Authors:  Quancai Cai; Chunping Zhu; Yuan Yuan; Qi Feng; Yichao Feng; Yingxia Hao; Jichang Li; Kaiguang Zhang; Guoliang Ye; Liping Ye; Nonghua Lv; Shengsheng Zhang; Chengxia Liu; Mingquan Li; Qi Liu; Rongzhou Li; Jie Pan; Xiaocui Yang; Xuqing Zhu; Yumei Li; Bo Lao; Ansheng Ling; Honghui Chen; Xiuling Li; Ping Xu; Jianfeng Zhou; Baozhen Liu; Zhiqiang Du; Yiqi Du; Zhaoshen Li
Journal:  Gut       Date:  2019-03-29       Impact factor: 23.059

Review 7.  Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers: A Systematic Review.

Authors:  Natalia Calanzani; Paige E Druce; Claudia Snudden; Kristi M Milley; Rachel Boscott; Dawnya Behiyat; Smiji Saji; Javiera Martinez-Gutierrez; Jasmeen Oberoi; Garth Funston; Mike Messenger; Jon Emery; Fiona M Walter
Journal:  Adv Ther       Date:  2020-12-11       Impact factor: 3.845

Review 8.  Association of Helicobacter pylori Infection and Host Cytokine Gene Polymorphism with Gastric Cancer.

Authors:  Md Zeyaullah; Abdullah M AlShahrani; Irfan Ahmad
Journal:  Can J Gastroenterol Hepatol       Date:  2021-05-28

Review 9.  Gastric Cancer: How Can We Reduce the Incidence of this Disease?

Authors:  Caroline M den Hoed; Ernst J Kuipers
Journal:  Curr Gastroenterol Rep       Date:  2016-07

10.  Risk factors for gastric cancer and related serological levels in Fujian, China: hospital-based case-control study.

Authors:  Ping Yuan; Lan Lin; Kuicheng Zheng; Wen Wang; Sihan Wu; Liangxiang Huang; Bingshan Wu; Tiehui Chen; Xiaoqing Li; Lin Cai
Journal:  BMJ Open       Date:  2020-09-22       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.